Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03492281 · ClinicalTrials.gov registry record · Phase 3
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
A Phase 3 study, sponsored by Urovant Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,530
- Enrollment target
NCT03492281: Completed Phase 3 study, sponsored by Urovant Sciences.
NCT03492281 is a Phase 3 study that has completed, run by Urovant Sciences. The registered enrollment target is 1,530 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03492281, a Phase 3 study, has completed, sponsored by Urovant Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,530 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
Primary Outcome
A micturition/void is defined as "Urinated in Toilet" as indicated on the Patient Voiding Diary (PVD). The number of micturitions is defined as the number of times a participant voided in the toilet as indicated on the PVD. The average daily number of micturitions was calculated using the daily entries in the PVD (which was to be completed prior to each study visit) as the total number of micturitions that occurred on a Complete Diary Day (CDD) divided by the number of CDDs in the PVD. CFB was c
Interventions
- DRUG Tolterodine Tartrate ER
- DRUG vibegron
- DRUG Vibegron placebo
- DRUG Tolterodine placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,530 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 3 |
What the finished NCT03492281 record still lists
NCT03492281 is an interventional study that assigns participants to a tested intervention. Its 1,530 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% higher).
The record links to 0 conditions, and to 4 interventions - of which Tolterodine Tartrate ER is the first listed.
NCT03492281 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03492281 about?
NCT03492281 is a clinical study titled "A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)". This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
What is the current status of trial NCT03492281?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,530 participants. The study started on 2018-03-26. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT03492281?
The interventions under investigation include: Tolterodine Tartrate ER (DRUG), vibegron (DRUG), Vibegron placebo (DRUG), Tolterodine placebo (DRUG).
Who is sponsoring clinical trial NCT03492281?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03492281's enrollment target sits among peer trials
1,530 154th of 2000 higher than 1,846 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06393374 · 1,530 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- NCT07114510 · 1,530 participants · NA
Optimal Ventilation for Cardiac Arrest
- NCT06623097 · 1,528 participants · NA
Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study
- NCT06257082 · 1,526 participants · NA
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI